Comparing the Efficacy of TU-LESS and VNOTES for Hysterectomy of Enlarged Uterus
Launched by WEST CHINA SECOND UNIVERSITY HOSPITAL · Oct 27, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different surgical methods, TU-LESS and VNOTES, for women who need a hysterectomy due to an enlarged uterus caused by conditions like adenomyosis or uterine fibroids. Both techniques are minimally invasive, meaning they use smaller incisions or even natural openings in the body, which can lead to less pain and faster recovery compared to traditional surgery that requires larger cuts. The goal is to find out which method works better for patients in terms of healing and getting back to their normal activities.
To participate in this trial, women aged 18 to 70 who are facing surgery for an enlarged uterus are eligible. Participants will be randomly assigned to one of the two surgical methods, ensuring a fair comparison of their effectiveness. It's important to note that certain women, such as those with specific medical conditions or prior surgeries, may not qualify for the study. If you choose to participate, you will be closely monitored throughout the process, providing valuable information to help improve surgical options for future patients.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Eligible women aged 18-70 years.
- • Women with indications for enlarged uterine volumes who are planning to under go total hysterectomy.
- • Patients are willing to be randomly assigned to undergo any of both approaches.
- • Patients who are willing to sign the informed consent form.
- Exclusion Criteria:
- • Individuals who are virgins or have vaginal stenosis.
- • Patients requiring concurrent surgical intervention for conditions such as ovarian cysts or lesions of the vulva, vagina, appendix, etc.
- • Presence of malignancy or strong suspicion of malignancy that may alter the planned surgical approach.
- • History of two or more pelvic surgeries or suspected severe pelvic adhesions (rectovaginal examination suggesting rectovaginal endometriosis or limited uterine mobility).
- • History of peritoneal dialysis, pelvic radiation therapy and pelvic tuberculosis treated with laparoscopic surgery.
- • Uterine size exceeding that of a 3-month pregnancy (ultrasound indicates that the maximum uterine diameter line is greater than 12cm).
- • Patients with prolapse or pelvic inflammation.
- • Diabetes mellitus with poor blood glucose control.
- • Body mass index greater than 30 kg/m².
About West China Second University Hospital
West China Second University Hospital, affiliated with Sichuan University, is a leading medical institution in China renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a strong emphasis on multidisciplinary collaboration, the hospital fosters an environment that integrates patient care, education, and scientific inquiry. Its comprehensive facilities and expertise in various medical fields enable the hospital to conduct high-quality clinical trials aimed at improving treatment outcomes and enhancing the overall understanding of complex diseases. The hospital is dedicated to ethical research practices and strives to contribute to the global medical community through its findings and advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chengdu, Sichuan, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported